Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

242

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

242 results for “immune response to cancer;”

Learn how ShareScore rates datasets ↗
geo20/100

Dynamic IFNβ signalling underlies treatment response to immune checkpoint therapy in cancer [single-cell RNA-seq]

GEO Series GSE153942. Mus musculus. 12 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenJun 2022View details →
geo20/100

SMARCA4-mutant lung cancer disrupts anti-tumor immunity and immunotherapy response in a STING pathway-dependent manner [CUT&RUN]

GEO Series GSE278869. Homo sapiens. 12 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.

openGEO-OpenFeb 2025View details →
geo20/100

KDM5A inhibits anti-tumor immune response through downregulation of antigen presentation pathway in ovarian cancer

GEO Series GSE194361. Mus musculus. 9 samples. Type: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing.

openGEO-OpenApr 2022View details →
geo20/100

A plant immune protein enables broad antitumor response by rescuing microRNA deficiency in cancers

GEO Series GSE198147. Mus musculus; Homo sapiens. 127 samples. Type: Expression profiling by high throughput sequencing; Non-coding RNA profiling by high throughput sequencing; Other.

openGEO-OpenMar 2022View details →
geo20/100

Endocrine treatment potentiates antigen presentation and in combination with SMAC mimetics enhances an anti-tumor immune response in hormone receptor positive breast cancer

GEO Series GSE214054. Homo sapiens. 134 samples. Type: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing.

openGEO-OpenJul 2023View details →
geo20/100

Immune microenvironment of premenopausal estrogen receptor-positive/HER2-negative advanced breast cancer in response to treatment of Pembrolizumab, exemestane, and leuprolide

GEO Series GSE261815. Homo sapiens. 11 samples. Type: Expression profiling by array.

openGEO-OpenOct 2024View details →
geo20/100

Endocrine treatment potentiates antigen presentation and in combination with SMAC mimetics enhances an anti-tumor immune response in hormone receptor positive breast cancer (ATAC-seq WH/E2)

GEO Series GSE213484. Homo sapiens. 8 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.

openGEO-OpenJul 2023View details →
geo20/100

BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer [NanoString_IMM]

GEO Series GSE199616. Homo sapiens. 24 samples. Type: Expression profiling by array.

openGEO-OpenMay 2022View details →
geo20/100

Spatial tumor immune heterogeneity facilitates subtype co-existence and therapy response via AP1 dichotomy in pancreatic cancer [ChIP-seq]

GEO Series GSE276322. Homo sapiens. 11 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.

openGEO-OpenNov 2024View details →
geo20/100

Mammary Tumor-Derived Transplants as Breast Cancer Models to Evaluate Tumor-Immune Interactions and Therapeutic Responses

GEO Series GSE152403. Mus musculus. 24 samples. Type: Expression profiling by array.

openGEO-OpenDec 2021View details →
geo20/100

Targeting TREX1 induces innate immune response in drug resistant Small Cell Lung Cancer

GEO Series GSE272512. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenOct 2024View details →
geo20/100

Clonal tracing reveals the contribution of both cancer-intrinsic and -extrinsic mechanisms to the heterogeneity of responses to immune checkpoint blockade [ATAC-seq]

GEO Series GSE139473. Mus musculus. 6 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.

openGEO-OpenJul 2020View details →
geo20/100

Dynamic IFNβ signalling underlies treatment response to immune checkpoint therapy in cancer

GEO Series GSE153943. Mus musculus. 164 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenDec 2020View details →
zenodo20/100

Spatial Immune Associations of Immunotherapy Response in Non-Small Cell Lung Cancer by Multiplexed Tissue Imaging

Open the record for dataset details and reuse information.

opencc-by-4.0Dec 2023View details →
zenodo20/100

raw data related to project "Circulating biomarkers as predictors of gender-specific response to Immune Checkpoint Inhibitors in melanoma and non-small-cell lung cancer patients"

<p><strong>Sex-related differences in serum biomarker levels predict the activity and efficacy of Immune Checkpoint Inhibitors in advanced melanoma and Non-Small Cell Lung Cancer patients.</strong></p> <p><strong>Abstract&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></p> <p><strong>Background:</strong> Immune Checkpoint Inhibitors (ICIs) lead to durable response and a significant increase in long-term survival in patients with advanced malignant melanoma (MM) and Non-Small Cell Lung Cancer (NSCLC). The identification of serum cytokines that can predict their activity and efficacy, and their sex interaction, could improve treatment personalization.&nbsp;</p> <p><strong>Methods: </strong>In this prospective study, we enrolled immunotherapy-na&iuml;ve patients affected by advanced MM and NSCLC treated with ICIs. The primary endpoint was to dissect the potential sex correlations between serum cytokines (IL-1&beta;, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, GM-CSF, MCP-1, TNF-ɑ, IP-10, VEGF, sPD-L1) and the overall response rate (ORR). Secondly, we analyzed biomarker changes during treatment related to ORR, disease control rate (DCR), progression free survival (PFS) and overall survival (OS). Blood samples, collected at baseline and during treatment until disease progression (PD) or up to 2 years, were analyzed using Luminex xMAP or ELLA based technology.&nbsp;</p> <p>Three Luminex xMAP assays and two ELLA microfluidic cartridges were used to screen 28 immune-related biomarkers in 38 paired serum and citrate-theophylline-adenosine-dipyridamole (CTAD) plasma samples collected from 10 advanced melanoma or non-small cell lung cancer (NSCLC) patients at different time points during immunotherapy.</p> <p><strong>Results</strong>: Serum samples from 161 patients (98 males/63 females; 92 MM/69 NSCLC) were analyzed for treatment response. At baseline, IL-6 was significantly lower in females (F) <em>versus</em> males (M); lower levels of IL-4 in F and of IL-6 in both sexes significantly correlated with a better ORR, while higher IL-4 and TNF-ɑ values were predictive of a lower probability of ORR in F <em>versus</em> M. One hundred and sixty-five patients were evaluable for survival analysis: at multiple Cox regression, an increased risk of PD was observed in F with higher baseline values of IL-4, sPD-L1 and IL-10, while higher IL-6 was a negative predictor in males. In males, higher levels of GM-CSF predict a longer survival, whereas higher IL-1&beta; predicts a shorter survival. Regardless of sex, high baseline IL-8 values were associated with an increased risk of both PD and death, and high IL-6 levels only with shorter OS.&nbsp;</p> <p>Twenty-three of 28 biomarkers were detected both in serum and plasma by at least one of the assays, including IL-1&beta;, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, GM-CSF, IFN-&gamma;, TNF-&alpha;, VEGF, IP-10, MCP-1, eotaxin, fractalkine, G-CSF, IFN-&alpha;, IL-1RA, IL-13, IL-17A, MIP-1&beta; and sPD-L1. Conversely, FGF-2 and IL-1&alpha; were not detected in both matrices; GRO-&alpha; factor and EGF were detected only in serum and MIP-1&alpha; only in plasma. sPD-L1, MCP-1, IFN-&gamma;, IL-8, MIP-1&beta; and VEGF were, respectively, 1.15-, 1.44-, 1.83-, 2.43-, 2.82-, 6.72-fold higher in serum, whereas IL-10, IL-4, IL-2 and IL-5 were 1.05-, 1.19-, 1.92- and 2.17-fold higher, respectively, in plasma. IP-10 levels were higher in plasma but, as well as for VEGF, the bias serum versus plasma varied depending on the assay used (IP-10: &minus;5.7% to &minus;145%; VEGF: 115% to 165%). No significant differences were found for the remaining nine analyzed cytokines.</p> <p><strong>Conclusions</strong></p> <p>Serum IL-1&beta;, IL-4, IL-6, IL-10, GM-CSF, TNFɑ, and sPDL1 had a significant independent sex-related predictive impact on ORR, PFS and OS in melanoma and NSCLC patients treated with ICIs. These results will potentially pave the way for new ICI combinations, designed according to baseline and early changes of these cytokines and stratified by sex.&nbsp;</p> <p>The cytokine and sPD-L1 levels may differ between serum and plasma samples collected from cancer patients treated with immunotherapy, and the results obtained can be influenced by the different characteristics of the tested assays.</p>

restrictedcc-by-4.0Nov 2023View details →
ClinicalTrials.gov20/100

Pilot Study to Define the Immune Response Following Cryoablation of Invasive Breast Cancer

ClinicalTrials.gov study NCT03523299. IPD Sharing: NO. Countries: 0. Publications: 0.

closedIPD-NOFeb 2026View details →
geo20/100

Multi-omic approach identifies a transcriptional network coupling innate immune response to proliferation in the blood of COVID-19 cancer patients

GEO Series GSE164571. Homo sapiens. 12 samples. Type: Other.

openGEO-OpenNov 2021View details →
geo20/100

BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer

GEO Series GSE199618. Homo sapiens. 58 samples. Type: Expression profiling by high throughput sequencing; Expression profiling by array.

openGEO-OpenMay 2022View details →
geo20/100

A novel tumor-associated myeloid cell population inhibits antigen-specific immune responses in cancer patients

GEO Series GSE75042. Homo sapiens. 9 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenAug 2016View details →
geo20/100

SMARCA4-mutant lung cancer disrupts anti-tumor immunity and immunotherapy response in a STING pathway-dependent manner [ChIP-seq3]

GEO Series GSE288649. Homo sapiens. 1 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.

openGEO-OpenFeb 2025View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record